May 4th, 2022 Education, Understanding Intrathecal Therapy
Intrathecal Therapy (ITT) is the treatment and management of chronic pain through targeted drug delivery. Medication is introduced directly into the fluid around the spine, known as the intrathecal space, for faster, more powerful relief compared to oral treatments. The medication, in this case, morphine sulfate, is administered through a continuous microinfusion device (such as a pump) and doesn’t have to work its way through your body the way oral drugs do.
Intrathecal therapy can be used to treat chronic back and neck pain, sciatica, abdominal pain, pain as a result of a failed back or neck surgery, cancer pain, and reflex sympathetic dystrophy or complex regional pain syndrome.*
In order to be treated with injectable morphine sulfate through intrathecal therapy, the patient needs to undergo a relatively quick and simple procedure to implant the medication pump.
During the surgery, the microinfusion pump – a round, metal device about the size of a hockey puck* – is implanted into the abdomen, just under the skin. A catheter runs from the pump to the space around the spinal cord to deliver medication directly into the fluid around the spine in order to target specific receptors in the spinal cord. The space and fluid surrounding the spine are known as the intrathecal space, hence the name intrathecal therapy.
The morphine sulfate pump is then programmed specifically to the patient and their needs, as determined by their doctor or medical provider. Designed to slowly release medication over a period of time, the pump can either deliver the same amount of morphine sulfate each time or release different amounts at different times of the day. Dosage and timing are decided by the doctor prior to the implantation but can increase or decrease as needed.
A nurse or doctor will closely monitor the amount of morphine sulfate in the pump to ensure a patient never has an empty pump and to prevent morphine withdrawal. When it’s time to refill the device, a nurse or doctor inserts a needle through the patient’s skin and into the fill port on the top of the pump. The pump continues to provide medication without interruption to the patient.
Because morphine sulfate is always being released through the pump, intrathecal therapy is also known as continuous dosing. The idea of having opioids consistently running through their body might give patients pause, but treatment is an incredibly safe and more convenient way to consistently manage pain, as the relative potency (mg) of intrathecal drugs is 0.1 versus oral which is 30. That means the ratio is 300:1 from oral to intrathecal; in other words, you’d need 300 oral opioids to get the same effect as 1 dose of intrathecal morphine sulfate.
The biggest benefit of intrathecal therapy is it allows for ongoing pain relief. Patients don’t have to worry about the medicine wearing off and their pain rearing its ugly head again. Additionally, thanks to the targeted delivery of medication at the pain site, patients experience a substantial increase in pain relief compared to other therapies. With less pain and improved mobility, patients are better able to perform daily tasks and activities, resulting in more independence.
When patients use a non-compounded injectable morphine sulfate, such as FDA-approved MITIGO™, for chronic pain relief, they can rest assured their relief and symptoms won’t change from dose to dose. Compounded drugs can vary in potency and dosage, depending on how they are mixed. But, because non-compounded drugs don’t need to be mixed with anything, potency and dosage don’t often fluctuate and patients can expect the same results from each refill of their pump.
Other benefits of intrathecal therapy include:
Intrathecal therapy not only provides the highest amount of relief to a patient but also mitigates the risk of opioid dependency due to its targeted therapy.
When comparing intrathecal injectable morphine sulfate to oral opioids, the former is a preferred choice for pain management and is consistently more effective.
Advantages of using intrathecal injectable via a pump vs. oral morphine include:
For a more in-depth dive into the benefits of intrathecal therapy over oral medication, check out our blog post “Morphine Sulfate Injection: The Preferred Chronic Pain Treatment Option.”
If you suffer from chronic pain and aren’t getting relief with your current treatment, it’s time to talk to your doctor about the possibility of switching to intrathecal therapy.
If you’re a medical provider with a patient who could benefit from intrathecal therapy and you’re interested in learning more, sign up for one of our education programs or contact us to book a meeting with our team.
MITIGO™ (Morphine Sulfate Injection, USP – Preservative-free) is an opioid agonist, for use in continuous microinfusion devices and indicated only for intrathecal or epidural infusion in the management of intractable chronic pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate.
WARNING: RISKS WITH NEURAXIAL ADMINISTRATION; LIFE-THREATENING RESPIRATORY DEPRESSION; RISK OF ADDICTION, ABUSE, AND MISUSE; NEONATAL OPIOID WITHDRAWAL SYNDROME; and RISKS FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS
See full prescribing information for complete boxed warning.
Neuraxial administration of MITIGO is contraindicated in patients with:
Most serious adverse reactions were respiratory depression, apnea, circulatory depression, respiratory arrest, shock, and cardiac arrest. Other common frequently observed adverse reactions include: sedation, lightheadedness, dizziness, nausea, vomiting, and constipation.
To report SUSPECTED ADVERSE REACTIONS, contact Piramal Critical Care, Inc. at 1-888-822-8431 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
For additional Important Risk Information, including boxed warning, see enclosed Full Prescribing Information.
MITIGO™ (Morphine Sulfate Injection, USP – Preservative-free) is an opioid agonist, for use in continuous microinfusion devices and indicated only for intrathecal or epidural infusion in the management of intractable chronic pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate.
WARNING: RISKS WITH NEURAXIAL ADMINISTRATION; LIFE-THREATENING RESPIRATORY DEPRESSION; RISK OF ADDICTION, ABUSE, AND MISUSE; NEONATAL OPIOID WITHDRAWAL SYNDROME; and RISKS FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS
See full prescribing information for complete boxed warning.
Neuraxial administration of MITIGO is contraindicated in patients with:
Most serious adverse reactions were respiratory depression, apnea, circulatory depression, respiratory arrest, shock, and cardiac arrest. Other common frequently observed adverse reactions include: sedation, lightheadedness, dizziness, nausea, vomiting, and constipation.
To report SUSPECTED ADVERSE REACTIONS, contact Piramal Critical Care, Inc. at 1-888-822-8431 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
For additional Important Risk Information, including boxed warning, see enclosed Full Prescribing Information.